Pharmacor targets patent extension in fight over AstraZeneca’s Forxiga

Intellectual Property 2026-03-10 4:23 pm By Cindy Cameronne Sydney

Pharmacor wants to amend its defence in AstraZeneca’s suit over the Australian drug maker’s plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.